P1, N=18, Active, not recruiting, Cellenkos, Inc. | Trial completion date: Jan 2024 --> May 2024 | Trial primary completion date: Jan 2024 --> May 2024

9 months ago

Trial completion date • Trial primary completion date

CK0801

1year

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib (ASH 2023)

Adoptive therapy with allogeneic, cord blood-derived regulatory T cells (Tregs) (CK0801- HLA 3/ 6 match, fresh infusion) showed safety and early clinical signal in MF (Kadia et al., Blood. The preliminary analysis of this study evaluating CK0804 (CXCR4 enriched T regs cell therapy) as addition to ruxolitinib shows initial safety with no myelosuppressive adverse events and promising clinical activity. The study is actively enrolling participants (NCT05423691). MD Anderson Cancer Center has an institutional conflict of interest with Cellenkos related to the research presented herein.

1 year ago

Clinical

TGFB1 (Transforming Growth Factor Beta 1) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • IL13 (Interleukin 13) • TGFA (Transforming Growth Factor Alpha)

JAK2 V617F • JAK2 mutation

Jakafi (ruxolitinib) • CK0801

4years

[VIRTUAL] Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Show Safety and Early Clinical Signal in Primary Myelofibrosis (ASH 2020)

This is the first study to show that a single infusion of allogeneic CB derived Treg cells (CK0801) is well tolerated, feasible, and may be associated with clinical improvement in patients with immune related bone marrow disorders. Determining the optimal dose and schedule of the Treg cell infusion is ongoing.

4 years ago

Clinical

JAK2 (Janus kinase 2)

JAK2 mutation

CK0801